CSBio CSBio

X
[{"orgOrder":0,"company":"Sanofi","sponsor":"Fidia Farmaceutici Spa","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Continues Streamlining of Established Products with Sale of Anti-Inflammatory Drugs to Fidia Farmaceutici","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosenic Provides Update Regarding Current License Agreement With Phebra","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Medsenic"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets.

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Fidia Farmaceutici Spa

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Divestment March 23, 2021

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.

            Lead Product(s): Arsenic Trioxide

            Therapeutic Area: Immunology Product Name: OATO

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Phebra

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY